Home › Companies › EYEPOINT PHARMACEUTICALS INC. › 2023-2024

EYEPOINT PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and EYEPOINT PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-21 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 13Reported items
  • 194Asset managers
  • 2,204Fund votes
  • 2024-06-20Meeting date

Proxy season: 2023-2024 2024-2025

Explore EYEPOINT PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by EYEPOINT PHARMACEUTICALS INC.

These tallies are EYEPOINT PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-21 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

EYEPOINT PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-20
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Proposal 2: . Amendment to 2023 Long-Term Incentive Plan The Company's stockholders approved the 2023 Plan Amendment to (i) increase the number of shares of Common Stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual no 28,353,74715,905,586147,059 ---- Majority: yes
Proposal 3: . Amendment to 2019 Employee Stock Purchase Plan The Company's stockholders approved the Second 2019 Plan Amendment to increase the number of shares of Common Stock authorized for issuance thereunder by 250,000 shares. The voting on this proposal i 44,053,886205,116147,390 ---- Majority: yes
Proposal 4: . Non-Binding Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. The voting on 42,513,9141,715,072177,406 ---- Majority: yes
Proposal 5: . Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending De 46,085,482176,590138,364 ---- Majority: yes

Source: EYEPOINT PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-21 — read the filing on EDGAR.

How asset managers voted at the EYEPOINT PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 194 asset managers that disclosed a EYEPOINT PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of EYEPOINT PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE ACCOMPANYING PROXY STATEMENT.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 42,513,914AGAINST: 1,715,072

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: . Non-Binding Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclose”): 42,513,914 for, 1,715,072 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,885,701 outstanding shares: 85% for, 3% against (89% of the company cast a for/against vote).

The 193 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 98%
FOR: 98.1%AGAINST: 1.9%ABSTAIN: 0.0%
Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Essex Woodlands Management, Inc.13,498,2330 00For
T. Rowe Price6,727,1470 00For
Cormorant Asset Management, LP6,523,3170 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.4,981,9990 00For
SUVRETTA CAPITAL MANAGEMENT, LLC3,663,1240 00For
FRANKLIN ADVISERS INC3,608,1290 00For
Vanguard2,399,0730 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
BlackRock1,486,8090 00For
RA CAPITAL MANAGEMENT, L.P.1,457,0760 00For
State Street1,180,6210 00For
Federated Hermes1,155,9761,239 00For
Octagon Capital Advisors LP1,093,5030 00For
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)877,7900 00For
Laurion Capital Management LP790,8990 00For
Finepoint Capital LP656,6000 00For
Fiera Capital Corp600,7010 00For
PERCEPTIVE ADVISORS LLC588,5580 00For
Columbia Threadneedle517,0140 00For
Woodline Partners LP495,0000 00For
Candriam S.C.A.0383,000 00Against
Citadel348,3430 00For
SCHRODER INVESTMENT MANAGEMENT GROUP0305,122 00Against
HSBC0250,000 00Against
Northern Trust235,49417 00For

Showing the 25 largest of 193 asset managers. See all 193 in the interactive database.

2. To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares.

COMPENSATIONMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 44,053,886AGAINST: 205,116

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: . Amendment to 2019 Employee Stock Purchase Plan The Company's stockholders approved the Second 2019 Plan Amendment to increase the number of shares of Common Stock authorized for issuance thereunder by 250,0”): 44,053,886 for, 205,116 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,885,701 outstanding shares: 88% for, 0.5% against (89% of the company cast a for/against vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (10,024,186 for, 0 against).

FOR 100%
FOR: 10,024,186 (100.0%)
Largest asset managers voting on “To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase th” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,6160 00For
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC48,0000 00For
John Hancock43,5940 00For
Lincoln Financial40,0240 00For
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

3. To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%AGAINST 36%
FOR: 28,353,747AGAINST: 15,905,586

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: . Amendment to 2023 Long-Term Incentive Plan The Company's stockholders approved the 2023 Plan Amendment to (i) increase the number of shares of Common Stock authorized for issuance thereunder by 4,000,000 sh”): 28,353,747 for, 15,905,586 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,885,701 outstanding shares: 57% for, 32% against (89% of the company cast a for/against vote).

The 52 asset managers below cast 64% of the shares they voted on this item FOR (6,388,661 for, 3,635,895 against).

FOR 64%AGAINST 36%
FOR: 6,388,661 (63.7%)AGAINST: 3,635,895 (36.3%)
Largest asset managers voting on “To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase th” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price709,1792,059,466 00Against
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle0517,014 00Against
State Street101240,515 00Against
Victory Capital0110,664 00Against
Charles Schwab101,3230 00For
Equitable30,03751,772 00Against
Fidelity22,13255,110 00Against
New York Life067,140 00Against
DWS065,636 00Against
Lord Abbett059,927 00Against
TIAA050,403 00Against
BRIDGEWAY FUNDS INC048,000 00Against
John Hancock043,594 00Against
Lincoln Financial040,024 00Against
1290 Funds031,758 00Against
Prudential/PGIM028,450 00Against
ProShares023,446 00Against
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica020,156 00Against
AQR017,244 00Against
Northern Trust016,343 00Against

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

4. To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 46,085,482AGAINST: 176,590

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Proposal 5: . Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accou”): 46,085,482 for, 176,590 against, per its Form 8-K filed 2024-06-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,885,701 outstanding shares: 92% for, 0.4% against (93% of the company cast a for/against vote).

The 51 asset managers below cast 99.9% of the shares they voted on this item FOR (10,024,002 for, 34 against).

FOR 99.9%
FOR: 10,024,002 (100.0%)AGAINST: 34 (0.0%)
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting f” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,58234 00For
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC48,0000 00For
John Hancock43,5940 00For
Lincoln Financial40,0240 00For
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

5. Election of Directors: Anthony P. Adamis, M.D.

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (10,022,620 for, 0 against).

FOR: 10,022,620 (100.0%)ABSTAIN: 16 (0.0%)
Largest asset managers voting on “Election of Directors: Anthony P. Adamis, M.D.” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,6000 160For
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC48,0000 00For
John Hancock43,5940 00For
Lincoln Financial40,0240 00For
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

6. Election of Directors: David Guyer, M.D.

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.4%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (9,970,888 for, 0 against).

FOR: 9,970,888 (99.5%)ABSTAIN: 51,748 (0.5%)
Largest asset managers voting on “Election of Directors: David Guyer, M.D.” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,5870 290For
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC00 48,0000Abstain
John Hancock43,5940 00For
Lincoln Financial40,0240 00For
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

7. Election of Directors: Goran Ando, M.D.

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 95%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (9,484,494 for, 0 against).

FOR: 9,484,494 (94.6%)ABSTAIN: 538,142 (5.4%)
Largest asset managers voting on “Election of Directors: Goran Ando, M.D.” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,2710 3450For
Victory Capital00 110,6640Abstain
Charles Schwab101,3230 00For
Equitable31,1480 50,6610Abstain
Fidelity77,2420 00For
New York Life67,1400 00For
DWS00 65,6360Abstain
Lord Abbett00 59,9270Abstain
TIAA50,4030 00For
BRIDGEWAY FUNDS INC00 48,0000Abstain
John Hancock30,6300 12,9640For
Lincoln Financial22,1000 17,9240For
1290 Funds00 31,7580Abstain
Prudential/PGIM28,4500 00For
ProShares00 23,4460Abstain
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica00 20,1560Abstain
AQR00 17,2440Abstain
Northern Trust00 16,3430Abstain

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

8. Election of Directors: Jay S. Duker, M.D.

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (10,022,636 for, 0 against).

FOR: 10,022,636 (100.0%)
Largest asset managers voting on “Election of Directors: Jay S. Duker, M.D.” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,6160 00For
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC48,0000 00For
John Hancock43,5940 00For
Lincoln Financial40,0240 00For
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

9. Election of Directors: John B. Landis, Ph.D.

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 97%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (9,757,711 for, 0 against).

FOR: 9,757,711 (97.4%)ABSTAIN: 264,925 (2.6%)
Largest asset managers voting on “Election of Directors: John B. Landis, Ph.D.” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street4310 240,1850Abstain
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC48,0000 00For
John Hancock43,5940 00For
Lincoln Financial17,9240 22,1000Abstain
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

10. Election of Directors: Karen Zaderej

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (10,022,620 for, 0 against).

FOR: 10,022,620 (100.0%)ABSTAIN: 16 (0.0%)
Largest asset managers voting on “Election of Directors: Karen Zaderej” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,6000 160For
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC48,0000 00For
John Hancock43,5940 00For
Lincoln Financial40,0240 00For
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

11. Election of Directors: Nancy Lurker

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 97%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (9,754,786 for, 0 against).

FOR: 9,754,786 (97.3%)ABSTAIN: 267,850 (2.7%)
Largest asset managers voting on “Election of Directors: Nancy Lurker” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street4310 240,1850Abstain
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC48,0000 00For
John Hancock43,5940 00For
Lincoln Financial17,9240 22,1000Abstain
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

12. Election of Directors: Stuart Duty

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (10,022,636 for, 0 against).

FOR: 10,022,636 (100.0%)
Largest asset managers voting on “Election of Directors: Stuart Duty” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,6160 00For
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC48,0000 00For
John Hancock43,5940 00For
Lincoln Financial40,0240 00For
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

13. Election of Directors: Wendy DiCicco

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.4%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (9,970,888 for, 0 against).

FOR: 9,970,888 (99.5%)ABSTAIN: 51,748 (0.5%)
Largest asset managers voting on “Election of Directors: Wendy DiCicco” at EYEPOINT PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price2,768,6450 00For
Vanguard2,309,4550 00For
FRANKLIN STRATEGIC SERIES2,023,3290 00For
Federated Hermes575,9680 00For
BlackRock543,5490 00For
Columbia Threadneedle517,0140 00For
State Street240,5870 290For
Victory Capital110,6640 00For
Charles Schwab101,3230 00For
Equitable81,8090 00For
Fidelity77,2420 00For
New York Life67,1400 00For
DWS65,6360 00For
Lord Abbett59,9270 00For
TIAA50,4030 00For
BRIDGEWAY FUNDS INC00 48,0000Abstain
John Hancock43,5940 00For
Lincoln Financial40,0240 00For
1290 Funds31,7580 00For
Prudential/PGIM28,4500 00For
ProShares23,4460 00For
Advisors' Inner Circle Fund III21,6180 00For
AIG/SunAmerica20,1560 00For
AQR17,2440 00For
Northern Trust16,3430 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Largest EYEPOINT PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of EYEPOINT PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 49,885,701 shares outstanding at the time of that meeting.

Top EYEPOINT PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Essex Woodlands Management, Inc. 27.06%
2T. Rowe Price 13.49%
3Cormorant Asset Management, LP 13.08%
4ADAGE CAPITAL PARTNERS GP, L.L.C. 9.99%
5SUVRETTA CAPITAL MANAGEMENT, LLC 7.34%
6FRANKLIN ADVISERS INC 7.23%
7Vanguard 4.81%
8FRANKLIN STRATEGIC SERIES 4.06%
9BlackRock 2.98%
10RA CAPITAL MANAGEMENT, L.P. 2.92%

Reported EYEPOINT PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

EYEPOINT PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Cormorant Asset Management 14.98% DEF14A
Adage Capital 10.34% DEF14A
Suvretta Capital Management 10.32% DEF14A
BlackRock 9.95% 13F
S 9.57% 13G
Franklin Resources 9.30% DEF14A
Vanguard Group 7.61% 13F
Franklin Templeton 6.79% 13F
RA Capital Management 6.20% DEF14A
T. Rowe Price 4.94% 13F

Percentages above are of 49,885,701 shares outstanding, as reported by EYEPOINT PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from EYEPOINT PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At EYEPOINT PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-20, in the 2023-2024 proxy season, 194 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,204 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: EYEPOINT PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-21.

EYEPOINT PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.